Michael Andriole

Currently holds positions in Chimerix Inc and Endocyte Inc

3.1

3.1

Position	Company	Period
Chief Business Officer	Chimerix Inc	April 4, 2019 -
Chief Financial Officer	Endocyte Inc	Feb. 20, 2017 -

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings

Download results Settings

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	Company	B/S Transaction type	Nb. shares Price Value	Number of shares	Price	Value
2025-02-14	2025-02-13	Chimerix Inc (CMRX)	PlS Planned sale	74,837 +28.3% 19.73 US$4,782,901	74,837 +28.3%	19.73	US$4,782,901
2025-02-13	2025-02-13	Chimerix Inc (CMRX)	PrS Proposed sale	82,935 164.44 US$2,779,381	82,935	164.44	US$2,779,381
2025-01-31	2025-01-30	Chimerix Inc (CMRX)	PlS Planned sale	99,965 +7.6% 461.12 US$642,651	99,965 +7.6%	461.12	US$642,651
2025-01-30	2025-01-30	Chimerix Inc (CMRX)	PrS Proposed sale	2,500 4.00 US$10,000	2,500	4.00	US$10,000
2024-08-09	2024-08-08	Chimerix Inc (CMRX)	PrS Proposed sale	1,500 0.87 US$1,300	1,500	0.87	US$1,300
2024-08-09	2024-08-08	Chimerix Inc (CMRX)	PlS Planned sale	1,285 -0.3% 0.83 US$1,065	1,285 -0.3%	0.83	US$1,065
2024-02-16	2024-02-14	Chimerix Inc (CMRX)	PlS Planned sale	1,744 -0.4% 1.04 US$1,809	1,744 -0.4%	1.04	US$1,809
2024-02-14	2024-02-14	Chimerix Inc (CMRX)	PrS Proposed sale	2,000 1.05 US$2,100	2,000	1.05	US$2,100
2023-05-19	2023-05-18	Chimerix Inc (CMRX)	PP Planned purchase	51,700 +16.9% 1.14 US$59,150	51,700 +16.9%	1.14	US$59,150
2022-05-18	2022-05-17	Chimerix Inc (CMRX)	PP Planned purchase	15,000 +7.6% 1.71 US$25,635	15,000 +7.6%	1.71	US$25,635
2020-03-17	2020-03-16	Chimerix Inc (CMRX)	PP Planned purchase	33,300 +28.6% 1.43 US$47,522	33,300 +28.6%	1.43	US$47,522
2019-11-07	2019-11-06	Chimerix Inc (CMRX)	B Purchase	100,000 +inf% 1.56 US$156,000	100,000 +inf%	1.56	US$156,000